QNCX (Quince Therapeutics, Inc. Common Stock) Stock Analysis - News
Quince Therapeutics, Inc. Common Stock (QNCX) is a publicly traded Healthcare sector company. As of May 21, 2026, QNCX trades at $1.04 with a market cap of $16.22M and a P/E ratio of -0.64. QNCX moved +0.00% today. Year to date, QNCX is -96.22%; over the trailing twelve months it is -89.41%. Its 52-week range spans $0.79 to $45.50. Rallies surfaces QNCX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in QNCX news today?
Quince Therapeutics surges 53% after hiring LifeSci Capital for reverse merger review: Quince Therapeutics engaged LifeSci Capital as financial advisor to explore restructuring and strategic alternatives including a reverse merger. The stock jumped 53% to $0.34 after closing at $0.23 as investors assessed its failed Phase 3 NEAT trial, $5.8 M cash balance, and sub-$1 share delisting threat.
Benatti Luca sold 50.00K (~$173.50K) on Dec 26, 2025.
Thye Dirk bought 77.00K (~$53.90K) on Aug 30, 2024.
Thye Dirk bought 77.50K (~$53.47K) on Aug 29, 2024.
QNCX Analyst Consensus
QNCX analyst coverage data. Average price target: $0.00.
Common questions about QNCX
What changed in QNCX news today?
Quince Therapeutics surges 53% after hiring LifeSci Capital for reverse merger review: Quince Therapeutics engaged LifeSci Capital as financial advisor to explore restructuring and strategic alternatives including a reverse merger. The stock jumped 53% to $0.34 after closing at $0.23 as investors assessed its failed Phase 3 NEAT trial, $5.8 M cash balance, and sub-$1 share delisting threat.
Does Rallies summarize QNCX news?
Yes. Rallies summarizes QNCX news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is QNCX research on Rallies investment advice?
No. Rallies provides research, data, and educational context for QNCX. It does not provide personalized investment advice.
